title: Alarming spread of vancomycin resistant enterococci in Sweden since 2007.
abstract: The total number of persons infected or colonised with vancomycin-resistant enterococci mandatorily reported to the Swedish Institute for Infectious Disease Control increased dramatically during 2007 and 2008. During a period of twenty months from 1 July 2007 to 28 February 2009, a total of 760 cases were reported compared with 194 cases reported during the entire period from 2000 to 2006. This rise was mainly attributed to a wide dissemination of vancomycin resistant enterococci which started in a number of hospitals in Stockholm in the autumn of 2007 and was followed by dissemination in various healthcare facilities (hospitals and homes for the elderly) in a further two Swedish counties in 2008. The majority of the cases (97%) were acquired in Sweden and among these, healthcare-acquired E. faecium vanB dominated (n=634). The majority of these isolates had identical or closely related pulsed-field gel electrophoresis patterns indicating clonal dissemination in the affected counties. The median minimum inhibitory concentration of vancomycin was 32 mg/L (ranging from 4 to >128 mg/L) and of teichoplanin 0.12 mg/L (ranging from 0.06 to 0.25 mg/L). Particular emphasis was placed on countermeasures such as screening, contact tracing, cleaning procedures, education in accurate use of infection control practices as well as increasing awareness of hygiene among patients and visitors. With these measures the dissemination rate decreased substantially, but new infections with the E. faecium vanB strain were still detected.
authors.affiliation: Swedish Institute for Infectious Disease Control, Solna, Sweden.
authors.forename: T
authors.initials: T
authors.lastname: Soderblom
authors.forename: O
authors.initials: O
authors.lastname: Aspevall
authors.forename: M
authors.initials: M
authors.lastname: Erntell
authors.forename: G
authors.initials: G
authors.lastname: Hedin
authors.forename: D
authors.initials: D
authors.lastname: Heimer
authors.forename: I
authors.initials: I
authors.lastname: Hokeberg
authors.forename: K
authors.initials: K
authors.lastname: Kidd-Ljunggren
authors.forename: A
authors.initials: A
authors.lastname: Melhus
authors.forename: B
authors.initials: B
authors.lastname: Olsson-Liljequist
authors.forename: I
authors.initials: I
authors.lastname: Sjogren
authors.forename: J
authors.initials: J
authors.lastname: Smedjegard
authors.forename: J
authors.initials: J
authors.lastname: Struwe
authors.forename: S
authors.initials: S
authors.lastname: Sylvan
authors.forename: K
authors.initials: K
authors.lastname: Tegmark-Wisell
authors.forename: M
authors.initials: M
authors.lastname: Thore
mesh_terms: D024881:Drug Resistance, Bacterial; D016983:Enterococcus / Q000187:drug effects*; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D011159:Population Surveillance; D013548:Sweden / Q000453:epidemiology; D014640:Vancomycin / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D014640:Vancomycin